CORC

浏览/检索结果: 共53条,第1-10条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:46/0  |  提交时间:2019/12/05
Prognosis assessment of acute-on-chronic liver failure in patients with hepatitis B virus-related cirrhosis requires specific criteria 会议论文
作者:  Gu Wenyi;  Deng, Guohong;  Zheng, Xin;  Chen, Jinjun;  Wang, Xian-bo
收藏  |  浏览/下载:88/0  |  提交时间:2019/12/05
A Preliminary Study of Adaptive Task Selection in Explicit Evolutionary Many-Tasking 会议论文
2019 IEEE Congress on Evolutionary Computation, CEC 2019, Wellington, New zealand, 2019-06-10
作者:  Shang, Q.;  Zhang, L.;  Feng, L.;  Hou, Y.;  Zhong, J.
收藏  |  浏览/下载:2/0  |  提交时间:2019/12/02
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:36/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:38/0  |  提交时间:2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:30/0  |  提交时间:2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载:11/0  |  提交时间:2019/12/05
Long-Term Follow-up of Peginterferon alpha-2b (40kD, Y Shape) (Pegberon) Treatment of Hbeag-Positive Chronic Hepatitis B Patients in Phase III Study 会议论文
作者:  Wang, Guiqiang;  Hou, Fengqin;  Zhang, Mingxiang;  Zhang, Dazhi;  Peng, Yanzhong
收藏  |  浏览/下载:18/0  |  提交时间:2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载:11/0  |  提交时间:2019/11/19


©版权所有 ©2017 CSpace - Powered by CSpace